Nesfatin-1 Suppresses Inflammation in Bronchopulmonary Dysplasia by Regulating HMGB-1/TLR4/p65/NLRP3 Signaling Pathway

作者：Xiaoting Yang, Gang Luo, Feifeng Lou · 发表于：Discovery Medicine · 年份：2025 · DOI：10.24976/discov.med.202537196.83 · 被引用次数：4 · 研究领域：Neonatal Respiratory Health Research、Infant Nutrition and Health、Fatty Acid Research and Health

Background: Bronchopulmonary dysplasia (BPD) is a common respiratory disease in premature infants. Nesfatin-1 is considered for the treatment of BPD. This study aimed to explore the anti-inflammatory effect of nesfatin-1 in the treatment of BPD. Methods: Hyperoxia-induced newborn rats and transfected primary type II alveolar epithelial cells (AECIIs) were used to evaluate nesfatin-1's efficacy in treating BPD. Lung damage was assessed by means of wet-dry ratio measurement, Hematoxylin and Eosin staining, Masson staining, Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, and Western blotting. Interleukin 6 ( Il-6 ), tumor necrosis factor alpha ( Tnf-α ), and interleukin 1β ( Il-1β ) levels were measured by Enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR). Neutrophils in bronchoalveolar lavage fluid were counted. High mobility group box 1 (HMGB-1), Toll-like receptor 4 (TLR4), nuclear factor kappa-light-chain-enhancer of activated B cells p65 subunit (p65), and NOD-like receptor family pyrin domain containing 3 (NLRP3) expressions were analyzed using Western blotting, while NLRP3 expression was detected through immunohistochemistry. AECIIs' viability, apoptosis, and reactive oxygen species (ROS) levels were assessed using cell counting kit-8 (CCK8), flow cytometry, and immunofluorescence, respectively. An immunofluorescence approach was used to detect surfactant protein C and ROS levels. Results: ...